Vijaypd Ceutical (VIJAYPD)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 20.40% shows capital-efficient operations despite modest size.
• Promoter holding of 56.43% provides ownership alignment.
• Latest quarter remains profitable: ₹2 Cr net profit on ₹51 Cr sales.
• Sales grew 2.01% in a flat year, avoiding an outright decline.

Concerns

• Profit growth is -17.97%, yet P/E is 29.16; PEG of 14.51 indicates an expensive valuation for this growth.
• No dividend yield, so shareholders receive no income while waiting.
• Piotroski F-Score of 4/9 suggests weak financial fundamentals and possible balance-sheet stress.
• Net margin is thin at roughly 4% in the latest quarter, leaving little cushion.

AI Analysis

When I look at Vijaypd Ceutical, I am reminded that a business must first earn a decent return on capital before I care about the share price. The reported ROCE of 20.40% is genuinely respectable, and promoter holding of 56.43% suggests owners are aligned with minority shareholders. Yet the rest of the picture gives me pause. Sales grew barely 2.01%, and profit fell almost 18% in the latest year. At ₹85.70, the market capitalisation is ₹125 Cr, and the price-earnings ratio stands at 29.16. For a company with flat sales and shrinking earnings, you are paying a rich multiple reminiscent of a fast grower, not a slow-moving electrical equipment business. The PEG ratio of 14.51 makes that clear: the market has priced in growth that simply isn't in the numbers. Graham would insist on margin of safety; here I see little. The latest quarter's net profit of ₹2 Cr on sales of ₹51 Cr is an operating margin around 4% - thin, and no dividend is being paid to reward patient capital. The Piotroski F-Score of 4 out of 9 warns me that financial health is below average. I don't need to own every business. A prudent investor should demand a far lower price, or clear evidence that orders and margins are turning upward, before putting money here. Value is not the same as a low share price; at 29 times earnings with negative profit growth, the valuation assumes improvements that have not yet appeared. I would stay on the sidelines until the business shows genuine momentum and the price offers a margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer